Chemo Therapy Failure

Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer

The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]

By Malecare|2017-10-19T10:48:29-04:00April 1st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Uncategorized, Understanding APC, Zytiga|0 Comments

Xtandi Shows Activity in Men with Prostate Cancer Resistant to Chemotherapy and Zytiga

Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]

By Malecare|2017-10-19T10:48:35-04:00February 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, enzalutamide, Provenge, Uncategorized, Xtandi, Zytiga|0 Comments

Correcting the NICE Guidance for Xtandi – It is worse for Men with Progressive Advanced Prostate Cancer

After a great deal of confusion and what turned out to be an error on my part I wish to let you know that the NICE (The U.K.’s National Institute for Health and Care Excellence) Guidance I shared on the blog on January 28, 2014 (http://advancedprostatecancer.net/?p=4360 ) about enzalutamide (Xtandi) was not accurate. In my [...]

By Malecare|2020-02-04T08:50:07-05:00February 5th, 2014|abiraterone acetate, Advanced Prostate Cancer, Advocacy, Cabazitaxel, Chemo Therapy Failure, Drugs & Treatments, Enzalutamide (MDV-3100), Politics of Cancer, Uncategorized, Xtandi, Zytiga|2 Comments

PLATO – A New Phase 4 Clinical Trial Extending the Use of Xtandi & Combining It with Zytiga

The makers of Enzalutamide (Xtandi), Astellas Pharma US, Inc and Medivation, Inc have begun a Phase 4 clinical trial known as PLATO. The study is designed to evaluate the efficacy and safety of continued treatment with enzalutamide (Xtandi) plus abiraterone acetate (Zytiga) and prednisone as compared to treatment with Zytiga and prednisone alone in men [...]

By Malecare|2017-10-19T10:49:16-04:00November 13th, 2013|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Fail First Therapy, step therapy, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Living Through Chemo with the Support of Natural Immune System Boosts – Probiotics

Mama might have been correct, eat your yogurt. Many of us already know that a healthy gut with plenty of probiotics to support your gastrointestinal health is absolutely critical to boosting your immune system. Experts say that gut flora could account for as much as 80% of our immune system! A study from the University [...]

By Malecare|2017-10-19T10:49:30-04:00September 11th, 2013|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Diet and Supplements, Drugs & Treatments, General Information, How We Live, Uncategorized, Understanding APC|1 Comment

Commonly Used FDA Approved Treatments for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels

By Malecare|2017-10-19T10:49:31-04:00September 3rd, 2013|abiraterone acetate, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Choline C11, Drugs & Treatments, Enzalutamide (MDV-3100), General Information, Hormone Therapy, MDV3100, Uncategorized, Understanding APC, Xofigo, Xtandi, Zytiga|2 Comments

Evidence Against Step Therapy Being Good for Prostate Cancer Care

On August 13, 2013 I wrote an important post about the terrible practice beginning to rear its head called step therapy. Step therapy is the practice of insurance companies requiring less expensive drugs be prescribed prior to more expensive ones despite the comparative efficacy of the drugs and their different mechanisms of action. This practice [...]

By Malecare|2020-02-04T10:20:23-05:00August 26th, 2013|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), General Information, step therapy, Uncategorized, Understanding APC, Xtandi|0 Comments

Step Therapy with Zytiga & Xtandi – Two Equal Drugs Make Our Insurance Companies Our Doctors!

Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by [...]

By Malecare|2013-08-13T10:53:39-04:00August 13th, 2013|2nd line hormone therapy, Advanced Prostate Cancer, Advocacy, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Enzalutamide (MDV-3100), General Information, Hormone Therapy, Politics of Cancer, Uncategorized, Understanding APC, Xtandi, Zytiga|2 Comments

What is the Current Role of Taxanes in the Treatment of Metastatic Prostate Cancer?

Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]

By Malecare|2017-10-19T10:49:45-04:00June 19th, 2013|abiraterone acetate, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), Uncategorized, Understanding APC, Xofigo, Xtandi, Zytiga|2 Comments

Chemotherapy Every Two Weeks Might Be Superior to the Standard Every Three Week Schedule Currently Used

Chemotherapy with Docetaxel is usually given on a once every three (3) week schedule of 75 mg/m2 administered intravenously + prednisolone (10 mg/day p.o.) for men with advanced prostate cancer. In the cases when the side effects are too difficult for a man to tolerate, the dose is often reduced to 50 mg/m2 administered intravenously [...]

By Malecare|2020-02-04T11:38:07-05:00January 18th, 2013|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|1 Comment